Class action lawsuits against genetic testing companies over PGT-A
By Ruth Retassie,
PET
| 10. 21. 2024
Former IVF patients in the USA have filed class action lawsuits against several companies for misleading them about the efficacy of PGT-A.
Class action lawsuits have been filed against CooperGenomics, CooperSurgical, The Cooper Companies, Reproductive Genetic Innovations, Progenesis, and Natera by former patients to recuperate funds spent on preimplantation genetic testing for aneuploidy (PGT-A). The lawsuits allege that these companies engaged in consumer fraud and breach of warranty by selling PGT-A to IVF patients, without disclaiming that this test is unproven, experimental, and entails risks of both misdiagnosis and embryo damage during the biopsy. The plaintiffs and class action members claim they would not have purchased testing if given accurate information about its efficacy.
Paula Bliss, partner and co-founder of Justice Law Collaborative and counsel for the plaintiffs, said: 'Our clients have been forced to make consequential decisions based on PGT-A testing that was falsely marketed as having unproven benefits... we seek justice on their behalf.'
PGT-A is conducted to analyse the chromosomal makeup of embryos. The aim is to improve chances of a live birth...
Related Articles
By Carl Zimmer, The New York Times | 10.20.2026
For the first time, scientists say they have used viruses designed by artificial intelligence to treat a human patient.
Researchers announced on Tuesday that they had administered the virus, known as a phage, to a patient suffering from a deadly...
By Noah Fromson, HealthLab | 10.19.2026
Gene therapy is no longer the future of medicine — it’s reality. Treatments that replace, silence or edit genes are already changing clinical care.
There are more than 6,000 rare genetic disorders but only a fraction currently have treatable targets...
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...